Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jan 20;18(1):e0280448. doi: 10.1371/journal.pone.0280448

Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels

Manae Tatsumi 1, Takayuki Kishi 1, Satoru Ishida 1, Hiroki Kawana 2, Akiharu Uwamizu 2, Yuki Ono 1, Kouki Kawakami 1, Junken Aoki 2, Asuka Inoue 1,*
Editor: Agustín Guerrero-Hernandez3
PMCID: PMC9858409  PMID: 36668668

Abstract

Transient receptor potential (TRP) channels are activated by various extracellular and intracellular stimuli and are involved in many physiological events. Because compounds that act on TRP channels are potential candidates for therapeutic agents, a simple method for evaluating TRP channel activation is needed. In this study, we demonstrated that a transforming growth factor alpha (TGFα) shedding assay, previously developed for detecting G-protein–coupled receptor (GPCR) activation, can also detect TRP channel activation. This assay is a low-cost, easily accessible method that requires only an absorbance microplate reader. Mechanistically, TRP-channel-triggered TGFα shedding is achieved by both of a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and 17 (ADAM17), whereas the GPCR-induced TGFα shedding response depends solely on ADAM17. This difference may be the result of qualitative or quantitative differences in intracellular Ca2+ kinetics between TRP channels and GPCRs. Use of epidermal growth factor (EGF) and betacellulin (BTC), substrates of ADAM10, improved the specificity of the shedding assay by reducing background responses mediated by endogenously expressed GPCRs. This assay for TRP channel measurement will not only facilitate the high-throughput screening of TRP channel ligands but also contribute to understanding the roles played by TRP channels as regulators of membrane protein ectodomain shedding.

Introduction

Transient receptor potential (TRP) channels comprise the largest cation-channel family and are regulated by various types of stimuli. In humans, 28 TRP channel subtypes have been identified, divided into seven subfamilies: TRPA, TRPC, TRPM, TRPML, TRPN, TRPP, and TRPV [1]. TRPV1, TRPA1, and TRPM8 are canonical members that were first identified as nociceptive receptors for capsaicin, allyl isothiocyanate (AITC), and menthol, respectively [25], compounds that act on nerve cells expressing TRP channels found in the oral mucosa, resulting in the respective perceptions of heat, pungent irritation, and coolness [6, 7]. In addition to nerve cells, TRP channels are expressed in many cell types, such as keratinocytes and immune cells, and are involved in various functions, including hair follicle formation and inflammation [811], making them attractive targets for drug discovery [12, 13].

Compounds acting on TRP channels can be evaluated by detecting the activation of TRP channel-induced intracellular signaling pathways. In most cases, TRP channel activation is assessed by measuring increases in intracellular Ca2+ concentrations using calcium mobilization assays or patch-clamp techniques; however, these experiments require expensive, specialized equipment (e.g., fluorescence measurement devices with liquid handling and patch-clamp amplifiers, respectively). Therefore, the development of a low-cost and easy-to-access method for evaluating TRP channel activation will be useful for researchers, especially those who have limited access to specialized equipment, and may broaden the TRP channel field.

We hypothesized that a transforming growth factor alpha (TGFα) shedding assay, which we have previously developed for detecting G-protein-coupled receptor (GPCR) activation [14], has the potential to detect TRP channel activation. The TGFα-shedding assay is based on the ectodomain shedding of the membrane-bound proform of alkaline phosphatase–tagged TGFα (pro-AP-TGFα). The activation of Gq-coupled or G12-coupled GPCRs induces TGFα ectodomain shedding via a disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), which cleaves pro-TGFα and other membrane proteins. ADAM17 is activated by protein kinase C (PKC) and intracellular Ca2+ elevation [1417]. Because TRP channels also trigger intracellular Ca2+ influx, we examined whether TRP channel activation can be detected using the TGFα-shedding assay.

In addition to ADAM17, ADAM10 also cleaves pro-TGFα, but the upstream mechanism associated with ADAM10 activation reportedly differs from that associated with ADAM17 activation. ADAM10 induces a TGFα-shedding response upon stimulation with calcium ionophores but is insensitive to the PKC activator tetradecanoyl phorbol acetate (TPA) that stimulates ADAM17 [17]. Our previous study showed that ADAM17 knockdown greatly suppressed the GPCR-induced TGFα-shedding response, suggesting that this response is independent of ADAM10 [14]. Activation of ADAM10 requires an increase in Ca2+ concentration, such as that induced by calcium ionophores, but the upstream physiological factors that lead to ADAM10 activation are poorly understood. Therefore, we examined whether TRP channels are upstream factors that activate ADAM10.

Here we demonstrate the ability of the TGFα-shedding assay to detect the activation of canonical, representative members of the TRP channel family. Interestingly, TRP channels induce not only the ADAM17-dependent but also the ADAM10-dependent TGFα-shedding response. We took advantage of this difference to minimize nonspecific responses mediated by endogenously expressed GPCRs by using epidermal growth factor (EGF) and betacellulin (BTC), substrates of ADAM10, as reporters in place of TGFα.

Materials and methods

Reagents and plasmids

Chemicals and reagents were purchased from Wako Pure Chemical Industries unless otherwise noted. Stealth small interfering RNA (siRNA) duplexes against mRNA encoding ADAM10 (target sequences are listed in Supplementary Information) and Stealth negative control siRNAs were purchased from Invitrogen. All TRP channels and GPCRs used in this study were of human origin and did not contain epitope tags. The sequences for TRP channels and GPCRs were cloned into mammalian expression vectors pcDNA3.1 (Invitrogen) and pCAGGS (gift from J. Miyazaki, Osaka University), respectively. A plasmid encoding alkaline phosphatase (AP)-TGFα was described previously [18]. Plasmids encoding AP-epidermal growth factor (EGF) and AP-betacellulin (BTC) were gifts from Shigeki Higashiyama, Ehime University [19].

Cell culture and transfection

Parent and ADAM17-deficient HEK293 cells were maintained in Dulbecco’s modified Eagle medium (DMEM, Nissui Pharmaceutical) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin (Sigma-Aldrich), and 100 μg/ml streptomycin (Gibco) (complete DMEM) in a 37°C incubator with 5% CO2. Transfection of plasmid DNAs was performed by lipofection reagent, polyethylenimine solution (PEI Max, Polysciences). Typically, cells were seeded in each well of a 12-well culture plate at a cell density ranging from 2 × 105 to 3 × 105 cells/mL in 1 mL complete DMEM and cultured for 1 day in a 37°C incubator with 5% CO2. For transfection, plasmid solution (see each assay condition below) was diluted in 50 μL Opti-MEM (Gibco) and mixed with 2.5 μL of 1 mg/mL PEI solution in 50 μL Opti-MEM. Cells were incubated for 1 day after transfection before performing any assays. Transfection of siRNA was performed using Lipofectamine RNAiMAX (Invitrogen). Cells were seeded in each well of a 12-well culture plate at a cell density of 1 × 105 cells/mL in 1 mL complete DMEM and cultured for 1 day in a 37°C incubator with 5% CO2. For transfection, 1.2 μL of 10 μM siRNA was diluted in 100 μL Opti-MEM and mixed with 2 μL RNAiMAX in 100 μL Opti-MEM. Cells were incubated for 1 day before performing plasmid transfection. Immediately prior to plasmid transfection, the cell supernatant was removed by aspiration, and fresh complete DMEM was added. Transfection then proceeded as described above.

TGFα-shedding assay

The TGFα-shedding assay was performed as described previously, with minor modifications [14]. Plasmid transfection was performed in a 12-well plate using a mixture of 250 ng plasmid encoding AP-TGFα (or AP-EGF or AP-BTC) and 100 ng plasmid encoding the receptor. After 1 day of culture, transfected cells were harvested by trypsinization, pelleted by centrifugation at 190 × g for 5 min, and suspended in 3.5 mL Hank’s Balanced Salt Solution (HBSS) containing 5 mM HEPES (pH 7.4). After incubation for 15 min at room temperature, cells were centrifuged at 190 × g for 5 min, and cell pellets were suspended in 3.5 mL HBSS. The resuspended cells were plated in a 96-well plate at 90 μl per well (typically 24 total wells [8 × 3]) and placed in a 37°C incubator with 5% CO2 for 30 min. After incubation, 10 μl of 10× compounds were added to each well and incubated for 1 h at 37°C in 5% CO2. Plates were centrifuged at 190 × g for 2 min. After centrifugation, 80 μl of supernatant from each well was transferred to a clean well in a new 96-well plate, leaving attached cells and 20 μl supernatant in the original well. An 80 μl volume of para-nitrophenyl phosphate (p-NPP) solution (10 mM p-NPP; 40 mM Tris-HCl, pH 9.5; 40 mM NaCl; 10 mM MgCl2) was then added to each well of both the supernatant plate and the cell plate. Absorbance at 405 nm (Abs405) was obtained for both plates before (background) and after 1-h incubation at 37°C using a microplate reader (SpectraMax 340 PC384, Molecular Devices). TGFα release was calculated as described in the Results. To evaluate TRPV1 antagonism, cells (plated in 80 μL per well) were pretreated with various concentrations of compounds 10 min before stimulation with capsaicin (100 nM). To evaluate TRPV1 inverse agonism, cells were incubated with capsazepine in the absence of capsaicin.

Generation of ADAM17-deficient cells

CRISPR-based targeted gene depletion was performed as described previously, with minor modifications [20]. In detail, ADAM17-deficient HEK293 cells were generated by the CRISPR/Cas9 system to mutate the gene encoding ADAM17 in parent HEK293 cells. An sgRNA construct targeting the gene encoding ADAM17 was designed using a CRISPR design tool (http://crispr.mit.edu) such that an SpCas9-mediated DNA cleavage site (3-bp upstream of the protospacer adjacent motif [PAM] sequence [NGG]) encompassed a restriction enzyme recognition site. The designed sgRNA sequence for ADAM17, including the SpCas9 PAM sequence, was 5′-GACCATTGAAAGTAAGGCCC-3′ (the Hae III restriction enzyme site is underlined). The designed sgRNA sequence was inserted into the Bbs I site of the pSpCas9 (BB)-2A-GFP (PX458) vector (a gift from Feng Zhang at the Broad Institute; Addgene plasmid No. 48138). The correct insertion of the sgRNA sequence was verified by Sanger sequencing (Fasmac). To generate ADAM17-deficient cells, HEK293 cells were seeded into a 10-cm culture dish and incubated for 24 h before transfection. The PX458 plasmid encoding the sgRNA and SpCas9-2A-GFP was transfected into cells using Lipofectamine 2000 (Thermo Fisher Scientific). After 3 days, the cells were harvested and processed for the isolation of GFP-positive cells (~5% of cells) using a fluorescence-activated cell sorter (SH800; Sony). After the expansion of clonal cell colonies using a limiting dilution method, clones were analyzed for the incorporation of the mutation in the targeted gene by restriction enzyme digestion. Candidate clones that harbored restriction enzyme–resistant PCR fragments were further assessed for genomic DNA alterations by TA cloning [21]. The PCR primers used to amplify the sgRNA-targeted sites were as follows: 5′-CCATAACTCCAGGGTGGCTC-3′ and 5′-GAGAGACTCCTCACCTGCAC-3′.

Data analysis

Concentration–response curves were fitted for all data using the Nonlinear Regression: Variable slope (four parameters) function in the GraphPad Prism 9 software (GraphPad), with the setting of absolute Hill Slope values less than 2. Sigmoid maximum effect (Emax), the negative log of the half-maximal excitation concentration (pEC50, a parameter for agonism), and the negative log of the half-maximal inhibitory concentration (pIC50, a parameter for antagonism and inverse agonism) were obtained. The details regarding normalization and replicates for each experiment are described in the figure legends.

Results

TRP channel activation is indicated by TGFα ectodomain shedding

First, we tested whether TRP channel activation triggers TGFα-shedding responses. We transfected plasmids encoding the AP-TGFα reporter with or without TRPV1-encoding plasmids in HEK293 cells (Fig 1A and 1B). After 24 h, we reseeded the transfected cells and stimulated them for 1 h with capsaicin, a prototypical TRPV1 agonist. If TRPV1 activation by capsaicin induces ectodomain shedding of AP-TGFα, we would expect to detect AP in the supernatant (Fig 1A and 1B). We isolated the supernatant and added p-NPP, a substrate for AP, to both the supernatant and the cells. AP activity can be evaluated by measuring para-nitrophenol (p-NP) production at Abs405 using an absorbance microplate reader (Fig 1B). Released AP-TGFα (%) can be determined by calculating the ratio of AP activity in the supernatant to the total AP activity (Fig 1B). We observed a TGFα-shedding response in a capsaicin concentration–dependent manner in TRPV1-transfected cells but not in mock-transfected cells (Fig 1C). The pEC50 value calculated from this concentration–response curve (Fig 1C) was 7.99 ± 0.05. We then expressed three other TRP channels, namely TRPA1, TRPM8, and TRPV3, and measured activation upon stimulation by their respective ligands, AITC, menthol, and 2-aminoethoxydiphenyl borate (2-APB). TGFα-shedding responses were observed under all tested receptor-transfected conditions (Fig 1D–1F). At high concentrations of AITC and 2-APB, the TGFα-shedding response was observed in mock-transfected cells, suggesting that these chemicals have off-target activities in HEK293 cells. However, the TGFα-shedding responses in TRPA1- and TRPV3-expressing cells were higher than those in mock-transfected cells. We evaluated the TRP channel–dependence of signals by subtracting the response in mock-transfected cells from the response in TRP channel–expressing cells (Fig 1D and 1F). The pEC50 values in TRPA1-, TRPM8-, and TRPV3-expressing cells were 5.17 ± 0.34, 3.58 ± 0.13, and 5.14 ± 0.22, respectively. The pEC50 values for all four types of channels were equivalent to or one order of magnitude greater than the values reported using other established methods [2226]. These results demonstrate that the TGFα-shedding assay sensitively detects agonist-induced activation of TRP channels.

Fig 1. TGFα-shedding assay can evaluate TRP channel activation.

Fig 1

(A) Schematic representation of the TGFα-shedding assay for detecting transient receptor potential (TRP) channel activation. TRPV1 is activated upon capsaicin stimulation, inducing AP-TGFα ectodomain shedding. Released AP-TGFα can be quantified by measuring AP activity in the supernatant based on the production of para-nitrophenol (p-NP) from para-nitrophenyl phosphate (p-NPP). (B) Schematic of the assay protocol: HEK293 cells transiently expressing AP-TGFα with or without TRP channel expression are reseeded onto 96-well plates and stimulated with a ligand. After the supernatant (sup) is transferred to a blank plate, AP-TGFα release is quantified by a colorimetric reaction to measure AP activity, using p-NPP as a substrate. AP-TGFα release (%) is calculated as the ratio of AP activity in the supernatant to the total AP activity. ΔAbs405 was calculated by subtracting the absorbance at 405 nm measured at 0 h [Abs405 (0 h)] from the absorbance at 405 nm measured at 1 h [Abs405 (1 h)], using 1.25 as a correction factor for the amount of supernatant transferred (80 of 100 μL). See Methods for details. (C) Concentration–response curve for the TGFα-shedding responses induced by TRPV1 activation upon capsaicin stimulation. The vehicle-treated condition is set as the baseline. Mock-transfected cells expressing only the AP-TGFα reporter were used as a control. (D–F) Concentration–response curves for the TGFα-shedding responses induced by TRPA1 (C), TRPM8 (D), and TRPV3 (E) activation upon AITC, menthol, and 2-APB stimulation, respectively. (G, H) Evaluation of antagonist activity (G) and inverse agonist activity (H) for capsazepine (CPZ). CPZ antagonism was examined in the presence of 100 nM capsaicin. Note that inverse agonism is shown without subtracting the vehicle-treated basal responses. In all panels, the symbols and error bars represent the mean and SEM, respectively, for three independent experiments performed in triplicate. For many data points, the vertical error bars are smaller than the symbols and, thus, are not visible.

Next, we attempted to assess whether antagonist activity is measurable. We measured the antagonist activity of capsazepine, a TRPV1 antagonist, in the presence of 100 nM of capsaicin [27]. The capsaicin-induced TGFα-shedding response was inhibited by increasing concentrations of capsazepine in TRPV1-transfected cells (Fig 1G). In mock-transfected cells, the shedding response was not observed at any tested concentration. The pIC50 value calculated from this concentration–response curve (Fig 1G) was 6.14 ± 0.064, which is consistent with a previous report [28], indicating that this assay can be used to evaluate antagonist activity.

Finally, we evaluated the inverse agonist activity of capsazepine, which refers to the inhibitory effect of capsazepine against spontaneous TRPV1 activation. Many TRP channels exhibit spontaneous activity that is observed just by expressing them in cultured cells, which is caused by constitutive activation of upstream factors of TRP channels [29]. This spontaneous activity causes chronic pain and degeneration in nerves and other cells, making it an important therapeutic target [30, 31]. We incubated TRPV1-expressing or mock-transfected cells with increasing concentrations of capsazepine for 1 h and measured the TGFα-shedding response. TRPV1-expressing cells showed a TGFα-shedding response without ligand stimulation, and the addition of capsazepine suppressed this response to a level similar to the level observed for mock-transfected cells (Fig 1H, the TGFα-shedding response is shown without subtracting the basal response). This result indicates that the TGFα-shedding assay can be used to evaluate the spontaneous activation of TRP channels and the inverse agonist activity of ligands. Therefore, the TGFα-shedding assay is useful for evaluating TRP channel activity.

TGFα-shedding response induced by TRPV1 activation depends on ADAM10 and ADAM17

We next investigated whether TRP channels and GPCRs induce the TGFα-shedding response through a shared sheddase. In a previous study, the GPCR-induced TGFα-shedding response was greatly suppressed by the siRNA-mediated knockdown of ADAM17 [14]. In the present study, the elimination of ADAM17 from HEK293 cells (ΔADAM17 cells; S1 Fig) completely abolished the TGFα-shedding response induced by the activation of the Gq-coupled histamine H1 receptor (H1R; Fig 2A), indicating that the GPCR-induced TGFα-shedding response is totally dependent on ADAM17. Stimulation of PKC by TPA induced a robust TGFα-shedding response, which was silenced in ΔADAM17 cells, suggesting that GPCR-induced TGFα shedding solely depends on the Gq–PKC–ADAM17 axis (Fig 2B).

Fig 2. TRP channel activation induces ectodomain shedding of EGFR ligands via both ADAM10 and ADAM17.

Fig 2

(A–C) Concentration–response curves showing the TGFα-shedding response in ADAM17-deficient HEK293 cells (ΔADAM17 cells). H1R (A) and TRPV1 (C) were evaluated as representatives of Gq-coupled GPCRs and TRP channels, respectively. TPA-induced shedding responses (B) were evaluated in cells expressing only AP-TGFα without receptors. (D) Concentration–response curve of TGFα-shedding responses induced by TRPV1 activation in ADAM10-siRNA-transfected parent cells or ΔADAM17 cells. (E–G) Comparisons of shedding responses induced by TRPV1 (E) and H1R (F) activation using AP-EGF and AP-BTC as reporters. The TPA-induced shedding response (G) was evaluated in cells expressing only AP-TGFα, AP-EGF, or AP-BTC, without receptors. (H, I) Concentration–response curves for the EGF- and BTC-shedding responses induced by TRPA1 (H) and TRPV3 (I) activation. In all figures, the symbols and error bars represent the mean and SEM, respectively, for three independent experiments performed in triplicate. For many data points, the vertical error bars are smaller than the symbols and, thus, are not visible.

We then examined whether TRPV1-induced TGFα shedding is mediated by ADAM17. Unlike H1R or TPA stimulation, capsaicin-induced TRPV1 stimulation remained capable of inducing a TGFα-shedding response in the ΔADAM17 cells, although the potency of capsaicin was lower in ΔADAM17 cells than in parent HEK293 cells (Fig 2C). This result indicates that other sheddases are involved in the TRPV1-induced TGFα-shedding response. Potent TGFα cleavage activity is also characteristic of ADAM10 [16, 32]. The TRPV1-induced TGFα-shedding response was evaluated in parent and ΔADAM17 cells transfected with ADAM10-siRNA or non-target siRNA. The TGFα-shedding response was not suppressed in ADAM10-siRNA–transfected parent cells but was greatly suppressed in ADAM10-siRNA–transfected ΔADAM17 cells (Fig 2D). These results indicate that TGFα-shedding response induced by TRP channels involves both the ADAM17 and ADAM10 (and possibly other ADAMs) pathways, whereas the GPCR-induced response depends solely on ADAM17.

Membrane protein substrates with high ADAM10 selectivity may be useful for measuring TRP channel ligands that induce non-specific responses, which may be mediated by endogenously expressed GPCRs, PKCs, or their signaling axes. EGF and BTC are known ADAM10 substrates [19, 33]. In parent cells, we expressed AP-tagged EGF (AP-EGF) or BTC (AP-BTC) in place of AP-TGFα and evaluated their shedding responses. TRPV1 activation induced both shedding responses, whereas H1R and PKC activation induced neither (Fig 2E–2G). Although the pEC50 and Emax values for AP-BTC and AP-EGF were both lower than those for AP-TGFα, AP-BTC and AP-EGF are useful for selectively detecting TRP channel-induced responses. We next examined whether the AP-EGF and the AP-BTC reporters lower the background signals observed for the TRPA1 and TRPV3 ligands. As shown in Fig 1C and 1E, AITC and 2-APB induced a TGFα-shedding response in mock-transfected cells. In TRPA1- and TRPV3-expressing cells, AITC and 2-APB, respectively, induced AP-EGF- and AP-BTC-shedding responses in concentration-dependent manners, whereas no shedding responses were observed in mock-transfected cells (Fig 2H and 2I). These results indicate that AP-EGF and AP-BTC are useful for TRP-selective measurements, with potentially low background responses. Therefore, unlike GPCRs, TRP channels can activate ADAM10, and this different ectodomain shedding mechanism allows for shedding assay improvements that facilitate the selective detection of TRP channel activation.

Discussion

In this study, we showed that the TGFα-shedding assay detects TRP channel activation and can be used to evaluate the agonist, antagonist, and inverse agonist activities of compounds. This assay has several advantages. First, it detects amplified signals based on the accumulation of pro-AP-TGFα in the supernatant and, thus, can detect the basal activity of TRP channels. The conventional Ca2+ mobilization assay is unsuitable for evaluating inverse agonistic activity because it captures a transient intracellular event. Second, the TGFα-shedding assay is less costly than traditional Ca2+ mobilization assay and patch-clamp method and can be performed with an easy-to-access absorbance microplate reader, a simple transient expression system, and low-cost reagents (p-NPP). One disadvantage of the TGFα-shedding assay includes the requirement for high exogenous AP-TGFα reporter expression, making this assay unsuitable for the analysis of primary cultured cells, in which the induction of exogenous expression can be challenging. We also recommend using AP-EGF and AP-BTC in place of AP-TGFα as reporters for measurements of TRP channel-ligand pairs to eliminate nonspecific responses.

Interestingly, ADAM10 is uniquely activated by TRP channels, despite both TRP channels and GPCRs inducing intracellular Ca2+ influx (Fig 2A–2D). This was evidenced by ectodomain shedding of EGF and BTC, substrates of ADAM10, which was triggered only by the downstream signal of TRP channels (Fig 2E–2I). The increase in intracellular Ca2+ concentration induced by TRP channel activation is high and long-lasting, whereas that induced by GPCRs is oscillatory and transient [3436]. Previous reports showed that Ca2+-induced ADAM10 activation is totally dependent on anoctamin 6 (ANO6), a Ca2+-sensitive phosphatidylserine scramblase [37, 38]. Based on these studies, we speculate that TRP channels activate ADAM10 via ANO6. The lack of GPCR-induced ADAM10 activation (Fig 2A) indicates no involvement of ANO6. ANO6 activation requires a high intracellular Ca2+ concentration ([Ca2+]i > 1 μM) [3941], and the increase in Ca2+ concentration or the duration of increased Ca2+ induced by GPCR activation is likely insufficient to activate ANO6. Although ADAM17 is activated by ANO6 [37], GPCR-triggered ADAM17 activation depends solely on PKC [14]. Thus, the distinct kinetics of intracellular Ca2+ concentrations associated with TRP channel and GPCR activation likely underlie their different signaling outcomes (Fig 3).

Fig 3. Possible mechanisms underlying ectodomain shedding of EGFR ligands by TRP channel and GPCR activation.

Fig 3

Putative molecular mechanisms for ectodomain shedding of EGFR ligands by TRP channels and Gq-coupled GPCRs activation. ADAM, a disintegrin and metalloproteinase domain-containing protein; ANO6, anoctamin 6; BTC, betacellulin; EGF, epidermal growth factor; GPCR, G protein–coupled receptor; PKC, protein kinase C; PS, phosphatidylserine; TGFα, transforming growth factor alpha; TRP, transient receptor potential.

ADAM10 and ADAM17 activation induced by the TRP channels may occur under both physiological and pathological conditions. A previous report showed that TRPV3 induces a TGFα-shedding response via activation of ADAM17, promoting hair follicle formation [9]; however, the physiological relationship between ADAM10 and TRP channels remains unknown. ADAM10 is associated with Alzheimer’s disease (AD) and is a potential therapeutic target [4244]. ADAM10 has α-secretase activity, which prevents amyloid-β formation [45, 46], and loss-of-function mutations in ADAM10 have been reported in AD patients, indicating that ADAM10 activation may be useful for the treatment of AD [47]. TRP channels, as well as ADAM10, are expressed in central nervous system neurons and are associated with psychiatric disorders [48, 49]. We believe that testing whether ADAM10 is activated by TRP channels under physiological conditions is worthwhile, in addition to determining whether targeting TRP channels to activate ADAM10 is potentially useful for the treatment of AD.

Supporting information

S1 Fig. Genomic sequences of ADAM17-deficient HEK293 cell line.

The sgRNA-target sequence is underlined. The arrow indicates a putative double-stranded break site. The restriction enzyme site (Hae III) is highlighted in red.

(TIF)

S1 Data. The numerical values underlying Figs 1 and 2.

(XLSX)

Acknowledgments

We thank Shigeki Higashiyama (Ehime University) for the AP-fused constructs; Makoto Arita (Keio University) for the helpful information on the TRP channel and TGFα shedding response; Makoto Tominaga (National Institute for Physiological Sciences) for the helpful discussion on TRP channel assays; Kayo Sato, Shigeko Nakano and Ayumi Inoue (Tohoku University) for their assistance in plasmid preparation; Tatsuya Ikuta (Tohoku University) for helpful discussion and manuscript editing.

Data Availability

All data are provided in the paper and its Supporting Information file.

Funding Statement

A.I. was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI grants 16H01377, 21H04791, 21H05113, JPJSBP120213501 and JPJSBP120218801; FOREST Program JPMJFR215T and JST Moonshot Research and Development Program JPMJMS2023 from Japan Science and Technology Agency (JST); Takeda Science Foundation; Uehara Memorial Foundation. M.T. received JSPS KAKENHI 22J10475. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Venkatachalam K, Montell C. TRP channels. Annual review of biochemistry. 2007;76:387–417. doi: 10.1146/annurev.biochem.75.103004.142819 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Colbert HA, Smith TL, Bargmann CI. OSM-9, a novel protein with structural similarity to channels, is required for olfaction, mechanosensation, and olfactory adaptation in Caenorhabditis elegans. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1997;17(21):8259–69. doi: 10.1523/JNEUROSCI.17-21-08259.1997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–24. doi: 10.1038/39807 [DOI] [PubMed] [Google Scholar]
  • 4.Jordt S-E, Bautista DM, Chuang H-H, McKemy DD, Zygmunt PM, Högestätt ED, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature. 2004;427(6971):260–5. doi: 10.1038/nature02282 [DOI] [PubMed] [Google Scholar]
  • 5.McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature. 2002;416(6876):52–8. doi: 10.1038/nature719 [DOI] [PubMed] [Google Scholar]
  • 6.Leijon SCM, Neves AF, Breza JM, Simon SA, Chaudhari N, Roper SD. Oral thermosensing by murine trigeminal neurons: modulation by capsaicin, menthol and mustard oil. The Journal of physiology. 2019;597(7):2045–61. doi: 10.1113/JP277385 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wei JJ, Fu T, Yang T, Liu Y, Wang GR. A TRPA1 channel that senses thermal stimulus and irritating chemicals in Helicoverpa armigera. Insect molecular biology. 2015;24(4):412–21. doi: 10.1111/imb.12168 [DOI] [PubMed] [Google Scholar]
  • 8.Peier AM, Reeve AJ, Andersson DA, Moqrich A, Earley TJ, Hergarden AC, et al. A heat-sensitive TRP channel expressed in keratinocytes. Science (New York, NY). 2002;296(5575):2046–9. doi: 10.1126/science.1073140 [DOI] [PubMed] [Google Scholar]
  • 9.Cheng X, Jin J, Hu L, Shen D, Dong X-P, Samie MA, et al. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell. 2010;141(2):331–43. doi: 10.1016/j.cell.2010.03.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Oh M-H, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, et al. TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. Journal of immunology (Baltimore, Md: 1950). 2013;191(11):5371–82. doi: 10.4049/jimmunol.1300300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Baxter M, Eltom S, Dekkak B, Yew-Booth L, Dubuis ED, Maher SA, et al. Role of transient receptor potential and pannexin channels in cigarette smoke-triggered ATP release in the lung. Thorax. 2014;69(12):1080–9. doi: 10.1136/thoraxjnl-2014-205467 [DOI] [PubMed] [Google Scholar]
  • 12.Moran MM. TRP Channels as Potential Drug Targets. Annual review of pharmacology and toxicology. 2018;58:309–30. doi: 10.1146/annurev-pharmtox-010617-052832 [DOI] [PubMed] [Google Scholar]
  • 13.Koivisto A-P, Belvisi MG, Gaudet R, Szallasi A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nature reviews Drug discovery. 2022;21(1):41–59. doi: 10.1038/s41573-021-00268-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, et al. TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nature methods. 2012;9(10):1021–9. doi: 10.1038/nmeth.2172 [DOI] [PubMed] [Google Scholar]
  • 15.Yamashita Y, Okamoto M, Ikeda M, Okamoto A, Sakai M, Gunji Y, et al. Protein kinase C (PKC) increases TACE/ADAM17 enzyme activity in porcine ovarian somatic cells, which is essential for granulosa cell luteinization and oocyte maturation. Endocrinology. 2014;155(3):1080–90. doi: 10.1210/en.2013-1655 [DOI] [PubMed] [Google Scholar]
  • 16.Le Gall SM, Bobé P, Reiss K, Horiuchi K, Niu X-D, Lundell D, et al. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Molecular biology of the cell. 2009;20(6):1785–94. doi: 10.1091/mbc.e08-11-1135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Molecular biology of the cell. 2007;18(1):176–88. doi: 10.1091/mbc.e06-01-0014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, et al. Illuminating G-Protein-Coupling Selectivity of GPCRs. Cell. 2019;177(7):1933–47.e25. doi: 10.1016/j.cell.2019.04.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sahin U, Weskamp G, Kelly K, Zhou H-M, Higashiyama S, Peschon J, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. The Journal of cell biology. 2004;164(5):769–79. doi: 10.1083/jcb.200307137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Schrage R, Schmitz A-L, Gaffal E, Annala S, Kehraus S, Wenzel D, et al. The experimental power of FR900359 to study Gq-regulated biological processes. Nature communications. 2015;6:10156–. doi: 10.1038/ncomms10156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hisano Y, Kono M, Cartier A, Engelbrecht E, Kano K, Kawakami K, et al. Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes. The Journal of experimental medicine. 2019;216(7):1582–98. doi: 10.1084/jem.20181895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wang J, Tian W, Wang S, Wei W, Wu D, Wang H, et al. Anti-inflammatory and retinal protective effects of capsaicin on ischaemia-induced injuries through the release of endogenous somatostatin. Clinical and experimental pharmacology & physiology. 2017;44(7):803–14. doi: 10.1111/1440-1681.12769 [DOI] [PubMed] [Google Scholar]
  • 23.Yang F, Xiao X, Cheng W, Yang W, Yu P, Song Z, et al. Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nature chemical biology. 2015;11(7):518–24. doi: 10.1038/nchembio.1835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004;41(6):849–57. doi: 10.1016/s0896-6273(04)00150-3 [DOI] [PubMed] [Google Scholar]
  • 25.Xu L, Han Y, Chen X, Aierken A, Wen H, Zheng W, et al. Molecular mechanisms underlying menthol binding and activation of TRPM8 ion channel. Nature communications. 2020;11(1):3790–. doi: 10.1038/s41467-020-17582-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Colton CK, Zhu MX. 2-Aminoethoxydiphenyl borate as a common activator of TRPV1, TRPV2, and TRPV3 channels. Handbook of experimental pharmacology. 2007;(179):173–87. doi: 10.1007/978-3-540-34891-7_10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bevan S, Hothi S, Hughes G, James IF, Rang HP, Shah K, et al. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. British journal of pharmacology. 1992;107(2):544–52. doi: 10.1111/j.1476-5381.1992.tb12781.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Belvisi MG, Miura M, Stretton D, Barnes PJ. Capsazepine as a selective antagonist of capsaicin-induced activation of C-fibres in guinea-pig bronchi. European journal of pharmacology. 1992;215(2–3):341–4. doi: 10.1016/0014-2999(92)90054-8 [DOI] [PubMed] [Google Scholar]
  • 29.Lev S, Minke B. Constitutive Activity of TRP Channels. Methods in enzymology. 2010;484:591–612. doi: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kitamura N, Nagami E, Matsushita Y, Kayano T, Shibuya I. Constitutive activity of transient receptor potential vanilloid type 1 triggers spontaneous firing in nerve growth factor-treated dorsal root ganglion neurons of rats. IBRO Reports. 2018;5:33–42. doi: 10.1016/j.ibror.2018.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Minke B. The TRP calcium channel and retinal degeneration. Advances in Experimental Medicine and Biology. 2002;514:601–22. doi: 10.1007/978-1-4615-0121-3_34 [DOI] [PubMed] [Google Scholar]
  • 32.Urriola-Muñoz P, Li X, Maretzky T, McIlwain DR, Mak TW, Reyes JG, et al. The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands. Journal of cellular physiology. 2018;233(3):2247–56. doi: 10.1002/jcp.26097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, Raines EW, et al. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. The Journal of biological chemistry. 2005;280(3):1826–37. doi: 10.1074/jbc.M408804200 [DOI] [PubMed] [Google Scholar]
  • 34.Nita II, Caspi Y, Gudes S, Fishman D, Lev S, Hersfinkel M, et al. Privileged crosstalk between TRPV1 channels and mitochondrial calcium shuttling machinery controls nociception. Biochimica et biophysica acta. 2016;1863(12):2868–80. doi: 10.1016/j.bbamcr.2016.09.009 [DOI] [PubMed] [Google Scholar]
  • 35.McDonough RC, Gilbert RM, Gleghorn JP, Price C. Targeted Gq-GPCR activation drives ER-dependent calcium oscillations in chondrocytes. Cell calcium. 2021;94:102363–. doi: 10.1016/j.ceca.2021.102363 [DOI] [PubMed] [Google Scholar]
  • 36.Seidman RA, Khattab H, Polanco JJ, Broome JE, Sim FJ. Oscillatory calcium release and sustained store-operated oscillatory calcium signaling prevents differentiation of human oligodendrocyte progenitor cells. Scientific reports. 2022;12(1):6160–. doi: 10.1038/s41598-022-10095-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Veit M, Koyro KI, Ahrens B, Bleibaum F, Munz M, Rövekamp H, et al. Anoctamin-6 regulates ADAM sheddase function. Biochimica et biophysica acta Molecular cell research. 2018;1865(11 Pt A):1598–610. doi: 10.1016/j.bbamcr.2018.08.011 [DOI] [PubMed] [Google Scholar]
  • 38.Bleibaum F, Sommer A, Veit M, Rabe B, Andrä J, Kunzelmann K, et al. ADAM10 sheddase activation is controlled by cell membrane asymmetry. Journal of molecular cell biology. 2019;11(11):979–93. doi: 10.1093/jmcb/mjz008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Grubb S, Poulsen KA, Juul CA, Kyed T, Klausen TK, Larsen EH, et al. TMEM16F (Anoctamin 6), an anion channel of delayed Ca(2+) activation. The Journal of general physiology. 2013;141(5):585–600. doi: 10.1085/jgp.201210861 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Shimizu T, Iehara T, Sato K, Fujii T, Sakai H, Okada Y. TMEM16F is a component of a Ca2+-activated Cl- channel but not a volume-sensitive outwardly rectifying Cl- channel. American journal of physiology Cell physiology. 2013;304(8):C748–59. doi: 10.1152/ajpcell.00228.2012 [DOI] [PubMed] [Google Scholar]
  • 41.Kim HJ, Jun I, Yoon JS, Jung J, Kim YK, Kim WK, et al. Selective serotonin reuptake inhibitors facilitate ANO6 (TMEM16F) current activation and phosphatidylserine exposure. Pflugers Archiv: European journal of physiology. 2015;467(11):2243–56. doi: 10.1007/s00424-015-1692-6 [DOI] [PubMed] [Google Scholar]
  • 42.Yuan X-Z, Sun S, Tan C-C, Yu J-T, Tan L. The Role of ADAM10 in Alzheimer’s Disease. Journal of Alzheimer’s disease: JAD. 2017;58(2):303–22. doi: 10.3233/JAD-170061 [DOI] [PubMed] [Google Scholar]
  • 43.Peron R, Vatanabe IP, Manzine PR, Camins A, Cominetti MR. Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment. Pharmaceuticals (Basel, Switzerland). 2018;11(1). doi: 10.3390/ph11010012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Marcello E, Saraceno C, Musardo S, Vara H, de la Fuente AG, Pelucchi S, et al. Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer’s disease. The Journal of clinical investigation. 2013;123(6):2523–38. doi: 10.1172/JCI65401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and biophysical research communications. 1984;120(3):885–90. doi: 10.1016/s0006-291x(84)80190-4 [DOI] [PubMed] [Google Scholar]
  • 46.De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature reviews Neurology. 2010;6(2):99–107. doi: 10.1038/nrneurol.2009.218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron. 2013;80(2):385–401. doi: 10.1016/j.neuron.2013.08.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Morelli MB, Amantini C, Liberati S, Santoni M, Nabissi M. TRP channels: new potential therapeutic approaches in CNS neuropathies. CNS & neurological disorders drug targets. 2013;12(2):274–93. doi: 10.2174/18715273113129990056 [DOI] [PubMed] [Google Scholar]
  • 49.Roedding AS, Gao AF, Au-Yeung W, Scarcelli T, Li PP, Warsh JJ. Effect of oxidative stress on TRPM2 and TRPC3 channels in B lymphoblast cells in bipolar disorder. Bipolar disorders. 2012;14(2):151–61. doi: 10.1111/j.1399-5618.2012.01003.x [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Agustín Guerrero-Hernandez

6 Dec 2022

PONE-D-22-29508Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channelsPLOS ONE

Dear Dr. Inoue,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The issues pointed by one of reviewers should be discussed in the corresponding section of the MS

Please submit your revised manuscript by Jan 20 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Agustín Guerrero-Hernandez

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"We thank Shigeki Higashiyama (Ehime University) for the AP-fused constructs; Makoto Arita (Keio University) for the helpful information on the TRP channel and TGF-α shedding response; Kayo Sato, Shigeko Nakano and Ayumi Inoue (Tohoku University) for their assistance in plasmid preparation. A.I. was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI grants 21H04791, 21H05113, JPJSBP120213501 and JPJSBP120218801; FOREST Program JPMJFR215T and JST Moonshot Research and Development Program JPMJMS2023 from Japan Science and Technology Agency (JST); Takeda Science Foundation; Uehara Memorial Foundation. M.T. received JSPS KAKENHI 22J10475. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"A.I. was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI grants H04791, 21H05113, JPJSBP120213501 and JPJSBP120218801; FOREST Program JPMJFR215T and JST Moonshot Research and Development Program JPMJMS2023 from Japan Science and Technology Agency (JST); Takeda Science Foundation; Uehara Memorial Foundation. M.T. received JSPS KAKENHI 22J10475. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this work, Tatsumi et al. developed a new molecular biology method to assay TRP channels activity exogenously expressed in cell lines, based on the use of a transforming TGF alpha shedding assay. This assay has the advantage of being low cost compared to calcium imaging or patch-clamp tecniques. That said, the information obtained by this method doesnt´t allow to monitorize TRP channel activity since the measurement is based on cummulated activity. Further, it is not useful to evaluate the activity of natively expressed TRP channels. Despite those limitations, this work might help the high-throughput screening of TRP channels ligand and to clarify the relationship between TRP channels and patho-physiologically relevant proteins as ADAM. Overall, the manuscript is well-written, well-structured, and the data support the conclusions.

As a main concern, authors show spontaneous TRPV1 activation (Figure 1H), however the origin of this activity remains unclear in the manuscript, since authors do not discuss this point or mention any reference supporting this. Is this TRPV1 spontaneous activation developed as a consequence of TGF alpha transfection? Has been this spontaneous activity previously reported in calcium imaging or patch-clamp experiments? If so, authors should add the corresponding references to the draft.

Reviewer #2: The present manuscript by Tatsumi and colleagues is an attempt to develop a low-cost and easy-to-access method for evaluating TRP channel activation. This will be useful for researchers, especially those who have limited access to specialized equipment, and may broaden the TRP channel field.

The present manuscript should be accepted in its present form.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Agustín Guerrero-Hernandez

2 Jan 2023

Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels

PONE-D-22-29508R1

Dear Dr. Inoue,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Agustín Guerrero-Hernandez

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Agustín Guerrero-Hernandez

11 Jan 2023

PONE-D-22-29508R1

Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels

Dear Dr. Inoue:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Agustín Guerrero-Hernandez

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Genomic sequences of ADAM17-deficient HEK293 cell line.

    The sgRNA-target sequence is underlined. The arrow indicates a putative double-stranded break site. The restriction enzyme site (Hae III) is highlighted in red.

    (TIF)

    S1 Data. The numerical values underlying Figs 1 and 2.

    (XLSX)

    Attachment

    Submitted filename: Response letter.docx

    Data Availability Statement

    All data are provided in the paper and its Supporting Information file.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES